Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 135500
Corporate User License Price USD 6000
Corporate User License Price INR 406500
Site License Price USD 4000
Site License Price INR 271000
Request a Quote

Report Title

Chlamydia Infections-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Chlamydia Infections-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Chlamydia Infections-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Chlamydia Infections-Pipeline Review, H1 2017



Executive Summary

Chlamydia Infections-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chlamydia Infections-Pipeline Review, H1 2017, provides an overview of the Chlamydia Infections (Infectious Disease) pipeline landscape.

Chlamydia is a sexually transmitted infection caused by a bacterium. Symptoms include burning feeling during urination, discharge from the penis or vagina, pain in the lower abdomen, bleeding between periods and pain and swelling around the testicles. Predisposing factors include age, multiple sex partners and history of prior sexually transmitted infection. Treatment includes antibiotics and pain medicine.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chlamydia Infections-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chlamydia Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chlamydia Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chlamydia Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 9 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 4 molecules, respectively.

Chlamydia Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Chlamydia Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Chlamydia Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Chlamydia Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Chlamydia Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Chlamydia Infections (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Chlamydia Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Chlamydia Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Chlamydia Infections-Overview

Chlamydia Infections-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Chlamydia Infections-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chlamydia Infections-Companies Involved in Therapeutics Development

Abera Bioscience AB

Evofem Inc

Lead Discovery Center GmbH

Merck & Co Inc

NanoBio Corp

Prokarium Ltd

QureTech Bio AB

SATT IDF Innov SAS

Selecta Biosciences Inc

SIGA Technologies Inc

Vault Pharma Inc

Chlamydia Infections-Drug Profiles

Ab-03-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

acALY-18-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Amphora-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia trachomatis vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia trachomatis vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chlamydia vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Inhibit CPAF for Chlamydia Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Chlamydia Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block Virulence for Chlamydia Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solithromycin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-669-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VPI-201-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chlamydia Infections-Dormant Projects

Chlamydia Infections-Product Development Milestones

Featured News & Press Releases

Dec 02, 2015: NanoBio's Chlamydia Vaccine Improves Clearance of Bacteria and Prevents Pelvic Inflammatory Disease in Mice

Aug 03, 2015: New Vaccine For Chlamydia to Use Synthetic Biology

Aug 03, 2015: SynbiCITE funds new vaccine for Chlamydia

Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection

Jul 20, 2011: Newly Designed Molecule Blocks Chlamydia Bacteria

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Chlamydia Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Chlamydia Infections, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Chlamydia Infections-Pipeline by Abera Bioscience AB, H1 2017

Chlamydia Infections-Pipeline by Evofem Inc, H1 2017

Chlamydia Infections-Pipeline by Lead Discovery Center GmbH, H1 2017

Chlamydia Infections-Pipeline by Merck & Co Inc, H1 2017

Chlamydia Infections-Pipeline by NanoBio Corp, H1 2017

Chlamydia Infections-Pipeline by Prokarium Ltd, H1 2017

Chlamydia Infections-Pipeline by QureTech Bio AB, H1 2017

Chlamydia Infections-Pipeline by SATT IDF Innov SAS, H1 2017

Chlamydia Infections-Pipeline by Selecta Biosciences Inc, H1 2017

Chlamydia Infections-Pipeline by SIGA Technologies Inc, H1 2017

Chlamydia Infections-Pipeline by Vault Pharma Inc, H1 2017

Chlamydia Infections-Dormant Projects, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Abera Bioscience AB, Evofem Inc, Lead Discovery Center GmbH, Merck & Co Inc, NanoBio Corp, Prokarium Ltd, QureTech Bio AB, SATT IDF Innov SAS, Selecta Biosciences Inc, SIGA Technologies Inc, Vault Pharma Inc


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand